You are here: Welcome to the MPKB » Welcome to the MPKB » Starting the Marshall Protocol » Working with your physician » Helping a concerned physician to become comfortable with the MP
Home

Differences

This shows you the differences between two versions of the page.

Link to this comparison view

Both sides previous revisionPrevious revision
Next revisionBoth sides next revision
home:starting:physician:reluctant [04.15.2019] – [Ascertain if reluctance is a provider problem or a bureaucracy problem] sallieqhome:starting:physician:reluctant [04.15.2019] – [Ascertain if reluctance is a provider problem or a bureaucracy problem] sallieq
Line 166: Line 166:
  
 I expect some other countries also have centralised control, in which case patients may need to research  medical reasons other than MP, why they should take Olmesartan in preference to some more usual prescription I expect some other countries also have centralised control, in which case patients may need to research  medical reasons other than MP, why they should take Olmesartan in preference to some more usual prescription
 +
 +=== Specific research ===
  
  
Line 172: Line 174:
 OLM refs to print;  for patient with doctor not a member of MPSS  OLM refs to print;  for patient with doctor not a member of MPSS 
 including information about dose relating to body weight, and dose timing including information about dose relating to body weight, and dose timing
-Dose timing 
  
 +
 +Dose timing
  
  
-  
  
 short extract for each research study follows: short extract for each research study follows:
Line 195: Line 197:
 cytokine damage (({{pubmed>long:88888888}})) cytokine damage (({{pubmed>long:88888888}}))
  
-    in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, and Olmesartan partly restored the synchronization (({{pubmed>long:23511341}})) +in circadian rhythms between HR and MAP in CKD: Synchronization between the two rhythms was progressively lost as renal function deteriorated, and Olmesartan partly restored the synchronization (({{pubmed>long:23511341}})) 
-    renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed>long:24384547}})) + 
-    olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects (({{pubmed>long:24842388}})) +renal protective effects of olmesartan may be better than those of other ARBs (({{pubmed>long:24384547}})) 
 + 
 +olmesartan may uniquely increase urinary ACE2 level, which could offer additional renoprotective effects (({{pubmed>long:24842388}}))  
  
 * treatment with olmesartan inhibited bone loss (({{pubmed>long:25363367}})) * treatment with olmesartan inhibited bone loss (({{pubmed>long:25363367}}))
Line 214: Line 219:
 improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed>long:23303198}})), improvement of glycemic control & insulin resistance was only observed in olmesartan group (({{pubmed>long:23303198}})),
 OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}})) OLM substantially delayed the development of left ventricular remodeling in type 2 diabetes (({{pubmed>long:25275251}}))
 +
 +
 Long term treatment Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint (({{pubmed>long:25001274}}))  Long term treatment Data suggest 40 & 80 mg olmesartan are able to significantly remodel & destiffen the arterial wall material during long-term treatment, partly independently of blood pressure, compared with 20 mg. hyper.ahajournals.org/content/early/2014/07/07/HYPERTENSIONAHA.114.03282.reprint (({{pubmed>long:25001274}})) 
 +
 +
 ===== Read more ===== ===== Read more =====
  
home/starting/physician/reluctant.txt · Last modified: 09.14.2022 by 127.0.0.1
© 2015, Autoimmunity Research Foundation. All Rights Reserved.